Interim Six-Month Results for MiyoSmart iQ

According to an announcement by y HOYA Vision Care, the company’s novel myopia control solution  builds on its clinically proven Defocus Incorporated Multiple Segments (D.I.M.S.) Technology, with Triple Enhanced Design (DIMS TED), in children aged 4–12 with progressive myopia.²

with the compelling clinical evidence behind MiyoSmart iQ, we are entering a new era of myopia control – where no myopia progression on average could be reached.

“These are the most impressive myopia control results seen so far with D.I.M.S Technology based spectacle lenses,” said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs, HOYA Vision Care. “The conversation has now moved beyond slowing down myopia progression; with the compelling clinical evidence behind MiyoSmart iQ, we are entering a new era of myopia control – where no myopia progression on average could be reached.”

MiyoSmart iQ advances HOYA’s proprietary D.I.M.S. Technology with Triple Enhanced Design, featuring three design enhancements that drive higher effectiveness compared to the previous MiyoSmart spectacle lenses. A smaller clear central zone, with defocus segments closer to the spectacle lens centre, intends to continuously activate the near-peripheral retina – identified as the region most responsive to myopic defocus. Higher defocus power enables a stronger myopic defocus signal, and an extended treatment zone with more defocus segments ensures extensive coverage of the child’s peripheral visual field, even for larger frames.^3,4

“With childhood myopia on the rise globally, MiyoSmart iQ represents the culmination of over a decade of HOYA innovation and research dedicated to addressing this challenge,” said John Goltermann Lassen, CEO, HOYA Vision Care. “With DIMS TED, we’ve developed our most advanced myopia control solution yet – elevating the standard of care in myopic children’s vision, by ushering in a new age in which there is no myopia progression on average.

“What’s more, myopic children and their families can be assured that MiyoSmart iQ spectacle lenses are crafted with aesthetics in mind and look just like standard SV spectacle lenses. This thoughtful innovation reflects our commitment to protecting children’s vision health and to providing Eye Care Professionals with the scientific foundation they need to deliver the highest standard of paediatric care.”

MiyoSmart iQ is currently available in major eye hospitals across China, with plans to continue the roll-out throughout 2026. MiyoSmart iQ will be sold alongside HOYA Vision Care’s well-established MiyoSmart spectacle lenses. Since its launch in 2018, more than 13 million MiyoSmart spectacle lenses have already been purchased by parents in over 50 countries worldwide.⁵

HOYA noted that the findings are based on interim data and should not be interpreted as long-term outcomes.

References

1. HOYA data on file. Myopia control efficacy of defocus incorporated multiple segments triple enhanced design spectacle lenses: 6-month results. 11/2025. Peer-reviewed publication will follow.
2. Tse DYY, et al. Myopia control efficacy of defocus incorporated multiple segments triple enhanced design spectacle lenses. The 41st Asia-Pacific Academy of Ophthalmology Congress, February 5–8, 2026. Abstract 205567. https://2026.apaophth.org/abstract/?code=205567 (Accessed: February 2026)
3. Swiatczak B, Scholl HPN, Schaeffel F. Retinal ‘sweet spot’ for myopia treatment. Sci Rep. 2024 Nov 5;14(1):26773. doi: 10.1038/s41598-024-78300-x.
4. Smith Iii EL, Arumugam B, Sankaridurg P, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res. 2020 Dec;177:32-40. doi: 10.1016/j.visres.2020.08.003.
5. Based on the number of MiyoSmart spectacle lenses sold and the number of countries selling MiyoSmart spectacle lenses according to HOYA’s sales data on file as of January 26.